Vertex Pharmaceuticals Inc. Stock Rises 5.6%, Outperforms Peers
Dow Jones2026/08/10 20:34This article was automatically generated by Dow Jones using technology from Automated Insights.
Shares of Vertex Pharmaceuticals Inc. rose 5.6% to $523.91 on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index falling 0.1% to 7,753.11 and Dow Jones Industrial Average falling 0.1% to 53,975.98.
This was the stock's second consecutive day of gains.
Vertex Pharmaceuticals Inc. closed 1.8% below its 52-week high of $533.67, which the company achieved on July 7th.
The stock outperformed some of its peers, as AbbVie Inc. rose 0.8% to $247.97, Krystal Biotech Inc. rose 1.6% to $331.59, and Arcturus Therapeutics Holdings Inc. fell 4.86% to $7.05.
Trading volume totaled 2.7 million, compared to the 50-day average of 1.6 million.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
August 10, 2026 16:34 ET (20:34 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Investment appeal stands out after pullback! Canadian pipeline giant Enbridge (ENB.US) upgraded by BMO Capital to "Outperform"
BMO has upgraded Enbridge's rating to "Outperform", believing that its recent pullback and $41 billion project backlog offer a good investment opportunity.
2-Yr Benchmark Govt Yields - U.S. vs Other Nations
2-Yr Benchmark Govt Yields - Germany vs Other Nations
10-Yr Benchmark Govt Yields - Germany vs Other Nations
Crypto prices
More
